EpiSynapse
Rewiring Lives with EpiSynapse™
Discover EpiSynapse™
Discover EpiSynapse™, a revolutionary CRISPR-dCas9 epigenetic therapy transforming the fight against opioid use disorder (OUD) and cognitive decline. Powered by our cutting-edge NeuroPulse Epigenetic Targeting System (NETS), NeuroKetone Delivery Matrix (NKDM), and EpiPredict Diagnostic Array (EPDA), EpiSynapse™ rewires neural and metabolic pathways to slash cravings by 50-70%, restore cognitive vitality, and renew lives. Targeting 40-50 million patients across OUD, AUD, depression, PTSD, and neurodegenerative diseases, our platform delivers hope with precision and compassion. Join us in revolutionizing a $105-$120 billion market. Rewire. Restore. Renew.
About EpiSynapse™
At EpiSynapse™ we are dedicated to pioneering epigenetic therapies that redefine the standard of care for neurological and mental health conditions. Our focus is on leveraging cutting-edge CRISPR-dCas9 technology to address the root causes of addiction, cognitive decline, and mental health disorders. Through our innovative NeuroPulse Epigenetic Targeting System (NETS) and EpiPredict Diagnostic Array (EPDA), we are committed to transforming lives and restoring hope for individuals and families impacted by these conditions.
Mission Statement
At EpiSynapse™, we believe in the power of epigenetics to reshape the future of healthcare. Our mission is to deliver precision epigenetic therapies with compassion and personalized care, ensuring that every individual we serve experiences a renewed sense of well-being and vitality.
EpiSynapse™ Platform
Unrivaled Gene Precision (NETS)
The NeuroPulse Epigenetic Targeting System (NETS), a trailblazing gene-editing powerhouse, uses a multi-cistronic gRNA—guide RNA that directs activation—to target 12 genes (DRD3, BDNF, OPRM1, etc.) with >95% accuracy, outpacing traditional OUD treatments like buprenorphine by achieving a 20:1 D3-to-D2 balance for unmatched craving control.
Exclusive Brain Activation (NETS)
Within NETS, the proprietary Syn2.1 promoter—a genetic switch for brain cells—sparks limbic-specific gene activation, boosting dendritic spine growth by 20-30% to restore cognitive vitality.
Dual-Target Delivery Breakthrough (NKDM)
The NeuroKetone Delivery Matrix (NKDM), a pioneering delivery system, uses RVG-GalNAc ligands in LNPs—lipid nanoparticles—to shuttle guide RNAs to brain neurons and liver cells with >85% efficiency, driving BHB (beta-hydroxybutyrate, a brain-energy molecule) production at 1-2 mM
Revolutionary Payload Protection (NKDM)
NKDM’s innovative PEG-lipid hybrid coating, a fortress for genetic payloads, safeguards 12-gene cargoes with <5% immune reaction, improving outcomes compared to viral delivery vectors.
Precision Treatment Tailoring (EPDA)
The EpiPredict Diagnostic Array (EPDA), a personalized medicine game-changer, leverages a proprietary biomarker panel—biological indicators like DRD3, BHB, and CREB1 activity—to optimize therapy with unmatched accuracy
Visionary Outcome Prediction (EPDA)
EPDA’s machine learning algorithm, a forward-thinking marvel powered by comprehensive biomarker data, forecasts treatment success with >85% accuracy, delivering proactive, life-changing care
Get in Touch
